secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2022-10-24T23:59:59+00:00
Accession:  0001104659-22-110797
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aziyo Biologics appoints David Colpman to board; regains Nasdaq audit committee compliance
--------------------------------------------------------------------------------

- David Colpman appointed to Board of Directors and audit committee effective Oct. 20, 2022; board size increased to six.
- Colpman brings over 25 years of healthcare business development experience, including senior roles at Shire, Novo Nordisk, Glaxo Wellcome.
- Appointment resolves Nasdaq noncompliance with Rule 5605(c)(2) (audit committee independence deficiency) created by Dr. Mills' role change.
- Colpman currently serves as advisor to HighCape Capital, affiliate of HighCape Partners, a controlling stockholder of Aziyo.
- CEO Dr. Randy Mills highlights Colpman's transaction experience as valuable for strategic partnerships and near-term priorities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465922110797/0001104659-22-110797-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465922110797/tm2228791d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-110797

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer